Drug intelligence / Profile preview

TAK-583

Development stage: Phase 3
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-583 is an orally available small molecule drug that was developed by Takeda for the treatment of neuropathic pain, specifically targeting conditions such as postherpetic neuralgia and diabetic peripheral neuropathy. The precise mechanism of action for TAK-583 remains undefined in public sources. Clinical development reached Phase 2/3 trials but was discontinued after these studies failed to progress further. The drug is classified as an analgesic and was investigated primarily within the therapeutic areas of nervous system diseases and endocrinology/metabolic disease.

Other names: TAK 583TAK583TAK-583

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))

Beyond the preview

Go deeper on TAK-583.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-583.

Explore the full profile